Preparation and in vitro studies of [125I]IUDR-T101 antibody conjugate

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 2, 1999, Pages 91-98

  Chakrabarti, M C ^a   Paik, C H ^a   Carrasquillo, Jorge A ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD5; Endocytosis; Iodine; IUDR; Monoclonal antibody

Indexed keywords

ANTIBODY CONJUGATE; IDOXURIDINE; IODINE 125; MONOCLONAL ANTIBODY; POLYLYSINE;

ARTICLE; CANCER RADIOTHERAPY; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; ENDOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SKIN LYMPHOMA;

EID: 0032933273     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.91     Document Type: Article

References (34)

1. JA Carrasquillo, in 'Radioimmunotherapy of Leukemia and Lymphoma', ed. H. Wagner, 1996.
2. SM Larson. Clinical radioimmunodetection, 1978-1988: overview and suggestions for standardization of clinical trials. Cancer Res 1990;50:892s-898s.
3. ER DeSombre, B Shafii, RN Hanson, PC Kuivanen, and A Hughes. Estrogen receptor-directed radiotoxicity with Auger electrons: specificity and mean lethal dose. Cancer Res 1992;52:5752-5758.
4. WL Hughes, AC Weinblatt, and W Prensky. Chromosome damage in Chinese hamster cells produced by 1251-UdR at the site of its incorporation. Curr Top Radiat Res Q 1978;12:453-471.
5. AI Kassis, KS Sastry, and SJ Adelstein. Kinetics of uptake, retention, and radiotoxicity of 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987;109:78-89.
6. RL Warters and KG Hofer. Radionuclide toxicity in cultured mammalian cells. Elucidation of the primary site for radiation-induced division delay. Radiat Res 1977;69:348-358.
7. WD Bloomer and SJ Adelstein. 5-125I-iododeoxyuridine as prototype for radionuclide therapy with Auger emitters. Nature 1977;265:620-621.
8. EW Bradley, PC Chan, and SJ Adelstein. The radiotoxicity of iodine-125 in mammalian cells. I. Effects on the survival curve of radioiodine incorporated into DNA. Radiat Res 1975;64:555-563.
9. P Calabresi, SS Cardoso, SC Finch, MM Kligerman, CF von Essen, MY Chu, and AD Welch. Initial clinical studies with 5-iodo-2′-deoxyuridine. Can Res 1961;21:550-559.
10. SL Commerford. Biological stability of 5-iodo-2′-deoxyuridine labelled with iodine-125 after its incorporation into the deoxyribonucleic acid of the mouse. Nature 1965;206:949-950.
11. KG Hofer, CR Harris, and JM Smith. Radiotoxicity of intracellular 67Ga, 1251 and 3H. Nuclear versus cytoplasmic radiation effects in murine L1210 leukaemia. Int J Radiat Biol Relat Stud Phys Chem Med 1975;28:225-241.
12. KG Hofer, G Keough, and JM Smith. Biological toxicity of Auger emitters: molecular fragmentation versus electron irradiation. Curr Top Radiat Res Q 1978;12:335-354.
13. G Keough and KG Hofer. Molecular consequences of the Auger effect: the fate of iododeoxyuridine Mowing iodine-125 decay. Radiat Res 1976;67:224-234.
14. WD Bloomer, WH McLaughlin, RR Weichselbaum, RN Hanson, SJ Adelstein, and DE Seitz. The role of subcellular localization in assessing the cytotoxicity of iodine-125 labeled iododeoxyuridine, iodotamoxifen, and iodoantipyrine. J Radioanal Chem 1981;65:209-221.
15. PC Chan, E Lisco, H Lisco, and SJ Adelstein. Cell survival and cytogenetic responses to 1251-UdR in cultured mammalian cells. Curr Top Radiat Res Q 1978;12:426-435.
16. AI Kassis, WE Guptill, RA Taube, and SJ Adelstein. Radiotoxicity of 5-[125I]iodo-2′-deoxyuridine in mammalian cells following treatment with 5-fluoro-2′-deoxyuridine. J Nucl Biol Med 1991;35:167-173.
17. RW Klecker Jr, JF Jenkins, TJ Kinsella, RL Fine, JM Strong, and JM Collins. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Clin Pharmacol Ther 1985;38:45-51.
18. J Baranowska-Kortylewicz, SJ Adelstein, and AI Kassis. 5-iodo-2′-deoxyuridine-protein conjugates: synthesis and enzymatic degradation. Sel Cancer Ther 1990;6:1-13.
19. I Royston, JA Majda, SM Baird, BL Meserve, and JC Griffiths. Human T cell antigens defined by monoclonal antibodies: the 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. J Immunol 1980;125:725-731.
20. JA Carrasquillo, PA Bunn Jr, AM Keenan, JC Reynolds, RW Schroff, KA Foon, MH Su, AF Gazdar, JL Mulshine, RK Oldham, et al. Radioimmunodetection of cutaneous T-cell lymphoma with In-111 labeled T101 monoclonal antibody. N Engl J Med 1986;315:673-680.
21. E Boven, T Lindmo, JB Mitchell, and PA Bunn Jr. Selective cytotoxicity of 1251-labeled monoclonal antibody T101 in human malignant T cell lines. Blood 1986;67:429-435.
22. Y Naruki, JA Carrasquillo, JC Reynolds, PJ Maloney, JM Frincke, RD Neumann, and SM Larson. Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti-CD5 monoclonal antibody. Int J Rad Appl Instrum [B] 1990;17:201-207.
23. AM Zimmer, EH Kaplan, JM Kazikiewiez, R Goldman-Leikin, KA Gilyon, MS Dykewicz, WG Spies, EA Silverstein, SM Spies, and ST Rosen. Pharmacokinetics ofI-131 T101 monoclonal antibodies in patients with chronic Lymphocytic leukemia. Antibody Immunoconjugates Radiopharmacy 1988;1:291-302.
24. WL Hughes, SL Commerford, D Gitlin, RC Krueger, B Schultze, V Shah, and P Reilly. Deoxyribonucleic acid metabolism in vivo. I. Cell proliferation and death as measured by incorporation and elimination of iododeoxyuridine. Fed Proc 1964;23:640-648.
25. T Lindmo, E Boven, F Cuttitta, J Fedorko, and PA Bunn Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
26. K Lappalainen, A Urtti, I Jaaskelainen, K Syrjanen, and S Syrjanen. Cationic liposomes mediated delivery of antisense oligonucleotides targeted to HPV 16 E7 mRNA in CaSki cells. Antiviral Res 1994;23:119-130.
27. A Ehrfeld, F Planas-Bohne, and C Lucke-Huhle. Amplification of oncogenes and integrated SV40 sequences in mammalian cells by the decay of incorporated iodine-125. Radiat Res 1986;108:43-51.
28. JA Carrasquillo, JL Mulshine, PA Bunn Jr, JC Reynolds, KA Foon, RW Schroff, P Perentesis, RG Steis, AM Keenan, M Horowitz, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med 1987;28:281-287.
29. F Geissler, SK Anderson, and O Press. Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells. Cell Immunol 1991;137:96-110.
30. F Geissler, SK Anderson, P Venkatesan, and O Press. Intracellular catabolism of radiolabeled anti-mu antibodies by malignant B-cells. Cancer Res 1992;52:2907-2915.
31. MJ Mattes, GL Griffiths, H Diril, DM Goldenberg, GL Ong, and LB Shih. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer 1994;73:787-793.
32. DV Woo, DR Li, LW Brady, J Emrich, J Mattis, and Z Steplewski. Auger electron damage induced by radioiodinated iodine-125 monoclonal antibodies. Front Radiat Ther Oncol 1990;24:47-63; discussion 64-48.
33. RL Waiters, KG Hofer, CR Harris, and JM Smith. Radionuclide toxicity in cultured mammalian cells: elucidation of the primary site of radiation damage. Curr Top Radiat Res Q 1978;12:389-407.
34. SL Commerford, VP Bond, EP Cronkite, and U Reincke. Radiotoxicity of intranuclear 125I atoms not bound to DNA. Int J Radiat Biol Relat Stud Phys Chem Med 1980;37:547-554.